Table of Contents
Tirzepatide Provided greater improvement compared to basal insulin. A1c Measure postprandial glucose (PPG) levels in patients with type 2 diabetes (T2D) regardless of differences in baseline PPG or fasting serum glucose (FSG) levels.
- Tirzepatide provided better glycemic control than the others. insulin degludec and insulin glargine The SURPASS-3 and SURPASS-4 trials each showed efficacy, but the effects on FSG and PPG levels were not evaluated.
- In this post-hoc analysis, researchers investigated changes in various glycemic parameters in 3,314 T2D patients randomly assigned to receive tirzepatide (5, 10, or 15 mg), insulin degludec, or insulin glargine. was evaluated.
- Based on median baseline glucose values, patients were stratified into four subgroups: low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG.
- Outcomes of interest were changes in FSG, PPG, A1c, and body weight from baseline to week 52.
- Tirzepatide and basal insulin effectively reduced A1c, PPG levels, and FSG levels in all patient subgroups (all) at 52 weeks. P < .05).
- All three doses of tirzepatide significantly lowered both A1c and PPG levels than basal insulin (all doses). P < .05).
- In the high FSG/high PPG subgroup, greater reductions in FSG levels were observed with tirzepatide 10 mg and 15 mg doses compared to insulin glargine (both P < .05) and insulin degludec vs tirzepatide 5 mg (P < .001).
- Furthermore, at week 52, tirzepatide led to weight loss (P < .05), but insulin treatment increased weight (P < .05) in all subgroups.
“Treatment with tirzepatide was consistently associated with further reductions in PPG levels compared to insulin treatment across subgroups including participants with lower baseline PPG levels, resulting in greater reductions in A1c. connected,” the authors write.
The study was led and presented by Francesco Giorgino, MD, of the Department of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases at the University of Bari Aldo Moro in Bari, Italy. online in diabetes care.
Limitations include the post hoc nature of the study and the short duration of treatment. This study included only patients with diabetes and overweight or underweight. obesityTherefore, the study results may not be generalizable to other populations.
This study and the SURPASS trial were funded by Eli Lilly and Company. The four authors declared themselves employees and shareholders of Eli Lilly and Company. Other authors have declared several relationships with various sources including Eli Lilly and Company.